Epidermal growth factor receptor-2 (HER-2) is overexpressed in 20 to 25% of human breast cancers, which is associated with aggressive tumour growth and poor prognosis. Trastuzumab (Herceptin®) is a humanized monoclonal antibody directed against HER-2, the first highly selective form of therapy targeting HER-2 overexpressing tumours. Although initial trials indicated high efficacy and a favourable safety profile of the drug, the first large, randomized trial prompted a retrospective analysis of cardiac dysfunction in earlier trials utilizing trastuzumab. There has been ongoing debate on the cardiac safety of trastuzumab ever since, initiating numerous clinical and preclinical investigations to better understand the background of trastuzumab cardiotoxicity and evaluate its effects on patient morbidity. Here, we have given a comprehensive overview of our current knowledge on the cardiotoxicity of trastuzumab, primarily focusing on data from clinical trials and highlighting the main molecular mechanisms proposed.
Introduction
Trastuzumab (Herceptin®) is a humanized monoclonal antibody (mAb) against the erythroblastic leukaemia viral oncogene homolog 2 (ErbB2), also known as the human epidermal growth factor receptor-2 (HER-2). Although this transmembrane receptor tyrosine kinase plays an important role in the normal growth and development of various cell types, its overexpression in 20 to 25% of human breast cancers is associated with aggressive growth and poor prognosis (Slamon et al., 1987) . Trastuzumab became the first clinically used mAb against HER-2. The drug blocks HER-2 signalling by multiple mechanisms, including disruption of normal ErbB signal transduction via physically disabling HER-2 molecules to form dimers with each other or further members of the HER/ErbB family ( Figure 1 ). Being a highly selective therapeutic option, it promised a positive outlook for HER-2 positive breast cancer patients to finally be treated with a molecule generating fewer or none of the adverse effects associated with conventional chemotherapeutics.
Although early phase II trials (Pegram et al., 1998; Baselga et al., 1999) indicated high efficacy and a favourable safety profile of trastuzumab, an unexpectedly high rate of adverse cardiac events during the first phase III trial (Slamon et al., 2001 ) prompted a retrospective analysis of all cases of cardiac dysfunction (CD) in earlier trials utilizing trastuzumab (Seidman et al., 2002) (Tables 1 and 3) . It was noted during this analysis, however, that most of the patients analysed in that cohort had received earlier anthracycline therapy (Seidman et al., 2002) and that the observed CD in response to trastuzumab resembled the cardiomyopathy associated with previously described anthracycline cardiotoxicity (Singal and Iliskovic, 1998) . Since then, there has been an ongoing debate on the cardiac safety of trastuzumab, initiating clinical and preclinical trials to better understand the background of trastuzumab cardiotoxicity and evaluate its effects on patient morbidity. Here, we have attempted to provide a comprehensive overview of our current knowledge of this effect, focusing primarily on data from clinical trials. We also wish to highlight the major molecular mechanisms uncovered hitherto in the background of trastuzumab cardiotoxicity.
Two decades of clinical experience

Historical background: the road to clinical use
Trastuzumab is a humanized mAb against the extracellular domain of HER-2/ErbB2, a member of the HER/ErbB group of transmembrane receptors with intracellular tyrosine kinase activity. After its discovery in 1985 (Coussens et al., 1985) and demonstration of its presence in human mammary carcinoma (King et al., 1985) , HER-2 rapidly became the focus of intensive investigations. Its overexpression was associated with poorly differentiated, aggressively growing tumours with a high metastatic potential, comprising approximately 20-25% of all breast carcinomas (Slamon et al., 1987) . MAbs against HER-2 proved to effectively inhibit proliferation of such breast cancer cells (Hudziak et al., 1989) . Following humanization of the murine anti-HER-2 mAb 4D5 (Carter et al., 1992) , this new type of anticancer drug was ready to be tested in the clinical practice ( Figure 2 ).
The initial, groundbreaking trials that supported the approval of trastuzumab by the Food and Drug Administration (FDA) for metastatic breast cancer (MBC) did not report any significant cardiotoxic effect of the drug (Pegram et al., 1998; Baselga et al., 1999; Shak, 1999; Baselga, 2001) . Trastuzumab was found to be well tolerated in all doses from 10-500 mg i.v. both alone and in combination with cisplatin in phase I trials (Shak, 1999) . This was shortly followed by phase II trials, providing proof-of-principle that the agent might offer major benefit for some patients. The first such trial of trastuzumab used a loading dose of 250 mg followed by 100 mg every week for 10 weeks, and involved 46 women with immunohistochemically proven HER-2 positive MBC (Table 1 ., (Baselga et al., 1999) ). A total of 39 patients with similar disease status were enrolled in a combination study with cisplatin (Pegram et al., 1998) , where the same dose of trastuzumab was administered for 9 weeks, and gave an overall response rate of 11.6 and 24.3% respectively (Table 3) . Patients in these trials could continue treatment until toxic effects or disease progression occurred. None of these trials reported serious cardiac events that could be related to trastuzumab treatment. Based on this safe and favourable preliminary efficacy, clinical trials of trastuzumab involving large numbers of patients were warranted. The landmark phase II, multicentre trial conducted by Cobleigh et al., the first to utilize administration of trastuzumab corrected for body weight (Table 3) , had similar response rates described in previous smaller trials (Cobleigh et al., 1999) . This trial unveiled, however, that the extent of HER-2 positivity (grade 3 vs. grade 2) had a significant effect on time to disease progression (3.3 vs. 1.9 months respectively) and that patients with grade 3 positivity tended to have a higher response rate (18 vs. 6%, P = 0.06) to trastuzumab therapy. Dose escalation did not increase response rate in a trial in which 114 patients with MBC were administered either a loading dose of 4 mg·kg À1 followed by 2 mg·kg À1 trastuzumab each week or twice of this dose at the same frequency (Vogel et al., 2001) . Due to the long serum half-life of trastuzumab, however, higher doses of the drug allow infrequent dosing. Specifically, when given in a loading dose of 8 mg·kg À1 followed by 6 mg·kg À1 every third week, trastuzumab showed similar serum levels to those seen in earlier trials with weekly dosing (Leyland-Jones et al., 2003) . The pivotal, randomized, multicentre, phase III trial [ Table 1 , (Slamon et al., 2001 )] conducted to compare chemotherapy in combination with trastuzumab versus chemotherapy alone in patients with HER-2 positive MBC showed that addition of the antibody to standard chemotherapy significantly increased time to disease progression (7.4 vs. 4.6 months), objective response rate (50 vs. 32%) and duration of response (9.1 vs. 6.1 months). Trastuzumab also decreased death rate at 1 year (22 vs. 33%) and reduced the risk of death by 20%. The unexpectedly high number of cardiac adverse events during these trials, however, triggered a retrospective investigation of all clinical trials that had been using trastuzumab by an independent Cardiac Review and Evaluation Committee (CREC , Tables 1 and 3) , based on concerns with the cardiac safety of trastuzumab (Seidman et al., 2002) . The CREC defined CD as one of the following: (1) cardiomyopathy
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Figure 1
Cardiotoxicity of doxorubicin and anti-HER-2 treatment in breast cancer. Anti-HER-2 treatment results in diminished pro-survival signalling in cardiomyocytes. Gene expression, ATP-and nitric oxide production favouring survival and proliferation are attenuated. In parallel, without appropriate counterbalancing, pro-apoptotic and necrosis-inducing processes such as cytochrome-c release from mitochondria and an increase in intracellular calcium concentration can facilitate cell death. The addition of doxorubicin to the system boosts oxidative and nitrosative stress via increased mitochondrial and iron-dependent generation of superoxide, which then is transformed into hydrogen peroxide and peroxynitrite. These reactive oxygen and nitrogen species are capable of inducing oxidative DNA damage, further aggravating the imbalance between pro-survival and pro-apoptotic/necrotic signalling. Green lines represent pro-survival mechanisms, while red lines show pro-apoptotic/necrotic processes. Dashed lines indicate an indirect connection. Akt -protein kinase B; Cyt-C -cytochrome-c; Dox -doxorubicin; MAPK -mitogen activated protein kinase; NO -nitric oxide; NOS3 -endothelial nitric oxide synthase; NRG-1 -neuregulin-1; ONOO À -peroxynitrite; PI3K - Italics mark concurrent anthracycline and trastuzumab dosing. AUC -area under the plasma concentration-time curve; FEC -fluorouracil, epirubicin, and cyclophosphamide-containing chemotherapeutic regimen; MBC -metastatic breast cancer; NCI-CTCAENational Cancer Institute Common Toxicity Criteria for Adverse Events; NYHA -New York Heart Association classification; PD -progressive disease.
characterized by a decrease in cardiac left ventricular ejection fraction (LVEF) that was either global or more severe in the septum; (2) symptoms of congestive heart failure (CHF); (3) associated signs of CHF, including but not limited to S3 gallop, tachycardia or both; and (4) decline in LVEF of at least 5 to less than 55% with accompanying signs or symptoms of CHF or a decline in LVEF of at least 10% to below 55% without accompanying signs or symptoms (Seidman et al., 2002) . Of the 1219 treated patients (14% overall, range: 1-27%) analysed in the CREC report, 174 met at least one of the above criteria. Sixty-two (5% overall, range 1-16%) of these patients had New York Heart Association Functional Class III or IV CHF. Another important conclusion of this retrospective analysis was that all patients had been or were exposed to anthracyclines. Incidence rates were found to be greatest when trastuzumab and anthracyclines were used concomitantly (Tables 1-3 ) and diagnosed CD events began to increase at approximately 300 mg·m À2 of cumulative doxorubicin dose (Seidman et al., 2002) . The authors also concluded, however, that there might have been biased over-reporting of cardiac events in the trastuzumabcontaining arms of the trial; therefore, cautious interpretation of their results is necessary. The recognition that trastuzumab might have a significant adverse cardiac effect changed the design of subsequent trials. Concomitant administration of trastuzumab and anthracyclines in large clinical trials was replaced by sequential dosage, and patients with decreased baseline LVEF were ineligible for most of the trials initiated after the CREC report. Cardiac-related adverse events were prospectively defined and also advanced into becoming major dose-limiting toxicity criteria. Patients exposed to trastuzumab were carefully monitored not only for CHF but also for asymptomatic falls in LVEF in all studies. Temporary or permanent trastuzumab discontinuation and protocols of dose limitation based on cardiac events have also been incorporated into most trials conducted since. Tables 1-4 contain an overview of clinical trials with trastuzumab, with a focus on the drugs used and the consequential CD events (as defined in the appropriate trial).
Trastuzumab in combination with chemotherapeutic agents
Anthracyclines. Anthracyclines, despite their well-known cardiotoxicity, are widely used due to being among the most active chemotherapeutic agents in breast cancer. Most of the clinical trials in which trastuzumab and anthracyclines were concurrently administered (Bianchi et al., 2003; Untch et al., 2004 Untch et al., , 2010 Buzdar et al., 2005; Gennari et al., 2009) , reported even higher percentage (range: 7-75%) of any type of CD than Seidman et al. in their retrospective analysis ( Table 2) . Regardless of the criteria used to determine asymptomatic CD in these studies, there is a clear dependency of CD incidence on anthracycline dose, in the observed populations (Table 2) . Investigators of the randomized NOAH trial (Gianni et al., 2010) reported very low occurrence of CHF in their patients despite the similar dose and timing of anthracyclines employed. It is noteworthy, however, that these patients did not receive anthracyclines earlier (Table 1) . Another, single arm trial (Venturini et al., 2006) , on the other hand, had to be prematurely terminated due to reaching five cases (11%) of symptomatic CHF. In this trial, five additional patients (11%) experienced asymptomatic LVEF drops below an absolute LVEF of 45%. CHF incidence, however, remained less than 8% in the rest of the trials, most of the investigators reporting no such events.
Encapsulation of doxorubicin in liposomes was introduced in order to decrease cardiotoxicity of the drug. A randomized, phase III trial with pegylated liposomal doxorubicin (O'Brien et al., 2004) showed that encapsulation of doxorubicin did not alter its efficacy, but significantly reduced CD events. Trials utilizing either pegylated (Chia et al., 2006; Christodoulou et al., 2009; Martin et al., 2011; Rayson et al., 2012) or non-pegylated (Venturini et al., 2010; Amadori et al., 2011; Anton et al., 2011) liposomal doxorubicin concurrently with trastuzumab showed similar results (Table 2) . However, a recent phase III trial with non-pegylated liposomal doxorubicin (Baselga et al., 2014) reported that there was no significant improvement in progression free survival with the addition of this agent to the standard Figure 2 Timeline of development of anti-HER-2 treatment. Discovered in 1985, HER-2 rapidly emerged into the centre of focus after its linkage to poor clinical outcomes in breast cancer patients was shown. Proliferation of breast cancer cells was successfully decreased using mouse mAbs developed against HER-2, and humanization of the most active 4D5 enabled it to enter the clinical stage. Despite the unexpected adverse cardiac effect of trastuzumab, the drug was approved by the FDA to treat metastatic breast cancer in 1998. Since then, anti-HER-2 treatment options have broadened with the approval of lapatinib and pertuzumab in 2007 and 2012 respectively. FDA -Food and Drug Administration; mAb -monoclonal antibody. Italics mark concurrent anthracycline and trastuzumab dosing. DLC -dose limiting cardiotoxicity; LABC -locally advanced, non-operable breast cancer; LLN -lower limit of normal; MBC -metastatic breast cancer; NCI-CTC 2.0 -National Cancer Institute Common Toxicity Criteria version 2.0; PD -progressive disease. Italics mark concurrent anthracycline and trastuzumab dosing. AUC -area under the plasma concentration-time curve; FEC -fluorouracil, epirubicin, and cyclophosphamide-containing chemotherapeutic regimen; MBC -metastatic breast cancer; PD -progressive disease.
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paclitaxel-trastuzumab first-line therapy. The occurrence of CD also decreased by administering trastuzumab following completion of anthracycline dosing both in nonencapsulated (Dang et al., 2008; Aogi et al., 2013) and liposomal (Cortes et al., 2009 ) forms of doxorubicin (Table 2) .
Taxanes. Single-arm (Esteva et al., 2002; Leyland-Jones et al., 2003; Burstein et al., 2003a; Gori et al., 2004; Coudert et al., 2006; Kelly et al., 2006; Dang et al., 2008; Untch et al., 2011; Aogi et al., 2013; Tolaney et al., 2015) or randomized (Marty et al., 2005; Joensuu et al., 2006; Wardley et al., 2010; Valero et al., 2011; Gianni et al., 2012; Baselga et al., 2012b) trials utilizing taxanes concurrently with trastuzumab in the adjuvant setting reported an increasing number of CD events (LVEF drop: 3-25%, CHF: 0-8%) with increasing prior exposure of patients to anthracyclines (Table 3) . Combination of taxanes with platinum salts (Pegram et al., 2004; Coudert et al., 2007; Slamon et al., 2011; Valero et al., 2011) or capecitabine (Wardley et al., 2010) did not affect the incidence of CD.
Other agents or administration protocols. (Tables 1 and 3) . In a randomized, phase III, non-inferiority trial [PHARE (Pivot et al., 2013) ], conducted in the hope of decreasing trastuzumab cardiotoxicity by administering the drug for 6 months instead of the standard 1 year, significantly fewer cardiac events occurred in the 6 month arm (Table 1) . Despite the favourable cardiac safety, investigators failed to show non-inferiority of the shorter regimen. In line with the results from PHARE, a retrospective analysis on a large cohort of early breast cancer patients requiring discontinuation of trastuzumab due to cardiotoxic effects, conducted recently by Gong et al., showed that early discontinuation of the drug was a strong independent predictor of cardiac events and clinically significant relapse (Gong et al., 2016) . Conversely, extending the treatment period to 2 years (Goldhirsch et al., 2013) or even longer (Pistilli et al., 2015) is not associated with better outcomes. It must also be noted, however, that trastuzumab cardiotoxicity did not seem to increase with sustained dosing in either studies. Altogether, these results provide further support for the 1 year regime as the standard of care. Although cyclophosphamide is known to have cardiotoxic effects (Gottdiener et al., 1981) , its contribution to cardiotoxicity in this setting is indistinguishable from that of anthracyclines, as they were administered in combination in all of the reviewed trials (Tables 2 and 4) .
Experience from large, randomized trialsknowledge from the past, outlook to the future et al., 2008) and Breast Cancer International Research Group (BCIRG) 006 (Slamon et al., 2011) showed that the addition of trastuzumab to anthracycline containing regimens in a sequential manner maintained CHF events below 4%, which was sustained over long-term follow-up (Gianni et al., 2011; Romond et al., 2012; de Azambuja et al., 2014) . Asymptomatic LVEF drops, however, were more prevalent in patients receiving trastuzumab (Table 1) , forcing the investigators to temporarily or permanently discontinue the drug in many cases. Furthermore, investigators of the BCIRG-006 trial reported that a subclinical toxic effect persisted for several years in patients who developed CD in the study arm receiving trastuzumab and anthracyclines (Slamon et al., 2011) . A meta-analysis of the above five and two further randomized trials (Buzdar et al., 2005; Spielmann et al., 2009) (Moja et al., 2012) ] in a population of 10 281 patients with early or locally invasive breast cancer. They concluded that although there is a benefit of trastuzumab in both overall survival and disease-free survival, patients need to be carefully selected for trastuzumab treatment as its cardiotoxic effects may erode the benefit observed in survival.
Of the analysed trials, FinHer was the sole study in which RR for CHF favoured trastuzumab over chemotherapy (RR: 0.5; 90% CI: 0.07 to 3.74). Its design was different from the others in terms of administering trastuzumab before the anthracycline (in this case, epirubicin), resulting in a lower incidence of CD events than in any prior large randomized trial (Joensuu et al., 2006) . Furthermore, this observed low incidence of CD was lasting (Joensuu et al., 2009) . NeoALTTO (Baselga et al., 2012a) and NeoSphere , two randomized studies using trastuzumab and epirubicin in a similar temporal sequence, provided further evidence of the feasibility of this regimen by reporting 1% of CD in the relevant arms of both cohorts. One previous, single-arm trial (Burstein et al., 2003a) that used a similar protocol reported worse cardiac outcome ( Table 2 ). The investigators in this trial, however, did not define any cardiac eligibility criteria; therefore, there is no information as to how many patients might have had anamnestic or concomitant cardiac-related disease in that cohort.
New drugs for HER-2 antagonismpertuzumab, lapatinib and ado-trastuzumab emtansine
Despite the significance of trastuzumab in up-to-date breast cancer treatment, concerns in connection with its cardiotoxicity and resistant tumours warranted development of other HER-2 signalling blocking agents. Trials with pertuzumab (Portera et al., 2008; Gianni et al., 2012; Baselga et al., 2012b; Schneeweiss et al., 2013) , lapatinib (Geyer et al., 2006; Dang et al., 2010; Guarneri et al., 2012; Baselga et al., 2012a; Moreno-Aspitia et al., 2013; Robidoux et al., 2013) and ado-trastuzumab emtansine [T-DM1, an antibody-drug conjugate, (Burris et al., 2011; Krop et al., 2012; Verma et al., 2012; Hurvitz et al., 2013; Krop et al., 2014; Yardley et al., 2015) ] have reported promising results both in terms of cardiac safety (Table 4) and anti-tumour BJP B T Nemeth et al.
efficacy. Interestingly, further blockade of HER-2 signalling by adding these new molecules to trastuzumab-containing regimens does not seem to increase cardiac morbidity compared with trastuzumab alone (Table 4) . A possible explanation for this might be that in the heart -as it will be discussed in more detail in the experimental background section -HER-2 appears to play a role only as a dimerization partner for other HER types. Consequently, new anti-HER-2 signalling drugs that exert their effect on different locations on HER-2 might not inhibit heterodimer formation with other HERs to the extent trastuzumab does (Figure 1 ). Although all of these drugs are now approved by the FDA to treat breast cancer (Figure 2 ), real-life data and further larger trials with longer follow-up will determine whether their cardiac safety is truly better than that of trastuzumab. Overall, there has been a significant evolution of trastuzumab administration in relation to both the type and timing of chemotherapeutics with which it could safely be coadministered. Clinical data from the last almost two decades indicate that (1) anthracyclines should be used sequentially, preferably following trastuzumab treatment; (2) anthracyclines might be more feasible to be used in a liposome-encapsulated form; (3) taxanes and trastuzumab given concurrently are relatively safe and effective; and (4) emerging new anti-HER-2 therapies are showing similar anticancer efficacy to trastuzumab, with a potentially better cardiac safety profile.
Experimental background: what we know
HER-2/ErbB signalling and trastuzumab
The mechanism of action and cardiotoxicity of trastuzumab is still not completely defined despite the considerable efforts that have been made to reveal the underlying mechanisms (Hudis, 2007) . Although early studies using HER-2/ErbB2 knockout mice have emphasized the importance of its downstream signalling in cardiovascular development, its role in the adult heart has only come into focus when patients receiving trastuzumab showed an increased incidence of heart failure and systolic dysfunction, as outlined above.
Permanent loss of the function of HER-2 is incompatible with life and leads to death in utero (Lee et al., 1995; Chan et al., 2002) . Subsequent investigations utilizing conditional cardiac disruption of the receptor in adult mice resulted in the development of spontaneous dilated cardiomyopathy (Crone et al., 2002; Ozcelik et al., 2002) . HER receptors can be activated by numerous ligands in vivo, including EGF (HER-1) or neuregulins (NRGs, HER-3 and -4) (Yarden and Sliwkowski, 2001) . Although to our current knowledge HER-2 itself is an orphan receptor, it is essential in the formation of heterodimers with other types of ErbB receptors, thereby increasing their activity (Karunagaran et al., 1996) . Moreover, HER-2 homodimers seem to be constitutively active (Kraus et al., 1987) and are more commonly found on the surface of cells overexpressing HER-2, such as breast cancer cells. ErbB downstream signalling includes activation of several important pathways such as phosphatidylinositol-3-kinase/Akt, MAPK and endothelial nitric oxide synthase, which are all major contributors in cell survival, mitochondrial function, sarcoplasmic reticulum calcium uptake, growth or proliferation [ Figure 1 , (Odiete et al., 2012; Varga et al., 2015) ]. In the heart, these pathways are important mostly in homeostatic processes and are activated predominantly through HER-4. As HER-2 is a transmembrane protein, it is a potential target for proteolysis. p95-HER-2, the smaller degradation product of this process, remains embedded in the plasma membrane in an active state. Furthermore, many breast cancers express p95-HER-2 via alternative translation of the HER-2 mRNA (Arribas et al., 2011) . Interestingly, this constitutively active fragment regulates several genes involved in developing and maintaining metastatic potential that are not influenced by the full-length receptor (Pedersen et al., 2009) . Also, tumours expressing p95-HER-2 tend to be resistant to trastuzumab but have a favourable response rate to the tyrosine kinase inhibitor lapatinib (Scaltriti et al., 2010; Arribas et al., 2011) .
Inactivation of HER-2 signalling by trastuzumab possibly comprises multiple effects. It appears that even though anti-HER-2 mAbs induce HER-2 homodimerization, this does not result in increased downstream signalling. Instead, the amount of HER-2 receptors on the cell surface was found to be reduced in response to trastuzumab, albeit via an uncertain mechanism (Hudziak et al., 1989; Sliwkowski et al., 1999) . Trastuzumab was also shown to decrease cell proliferation by inhibiting the cell cycle (Sliwkowski et al., 1999) , thus being more cytostatic than cytotoxic. Antibody-dependent cellular cytotoxicity is efficiently induced by trastuzumab as well (Carter et al., 1992) . The most likely mechanism involved in the cardiotoxicity of trastuzumab is the consequence of its interference with NRG/ErbB signalling (Pentassuglia et al., 2007) , as activity of both HER-3 and HER-4 is impaired when HER-2 is not available for formation of heterodimers (Graus-Porta et al., 1997) . Thus, the important cellular defensive and energy-generating systems of cardiomyocytes outlined above might not function properly in the presence of trastuzumab (Figure 1 ). Although this cardiotoxic effect was initially deemed reversible upon the discontinuation of the drug, experimental results imply that there might be lasting effects as a result of ultrastructural changes observed in rat ventricular myocytes (Sawyer et al., 2002) and in mice (ElZarrad et al., 2013) treated with trastuzumab. The drug also changed expression of genes involved in DNA repair and adaptation to stress (ElZarrad et al., 2013) . Therefore, further investigations to uncover the precise mechanisms of trastuzumab-induced effects in cardiomyocytes are needed.
Doxorubicin and trastuzumab -synergy in cardiotoxicity
A highly possible explanation for the additive cardiotoxic effect of doxorubicin and trastuzumab is that while doxorubicin increases the production of reactive oxygen and nitrogen species (ROS/RNS) (Doroshow and Davies, 1986; Pacher et al., 2002 Pacher et al., , 2003 Mukhopadhyay et al., 2009; Zhao et al., 2010) , blockade of HER-2 signalling results in decreased activation of survival pathways and exacerbates oxidative and nitrative stress [ Figure 1 , (Milano et al., 2014) ]. This leads to intracellular ROS accumulation, resulting in CD and cardiomyocyte apoptosis. NRG-1/ErbB signalling was shown to protect cardiac myocytes from anthracycline-induced apoptosis (Fukazawa et al., 2003) . Furthermore, calcium dysregulation and mitochondrial dysfunction, which might also be influenced by ErbB downstream signalling, may both play an important role in anthracycline-induced cardiomyopathy (Liu et al., 2007; Pointon et al., 2010; Rochette et al., 2015) . These results provide experimental support for the observation that disrupting ErbB signalling in cardiomyocytes during or immediately after anthracycline treatment worsens cardiac function in patients.
However, the exact mechanisms on how trastuzumab induces cardiotoxicity alone or in combination with doxorubicin are still unknown. Interestingly, while the doxorubicin-induced cardiotoxicity in general appears to be dose-dependent, trastuzumab does not appear to be more cardiotoxic with increasing cumulative doses. Changes in certain biomarkers might be useful in predicting adverse cardiovascular outcomes (Jensen and McLeod, 2013) .
Conclusions -future perspectives
Introduction of trastuzumab to chemotherapeutic regimes has indisputably changed the outlook of patients with HER-2 positive, aggressive breast cancer, significantly increasing their life expectancy. However, data on its cardiotoxicity overshadow the remarkable benefits observed in a subset of patients. Data from clinical and preclinical research have given some insight into the mechanisms of the cardiotoxicity of the drug since the first recognition of the prevalence of this phenomenon. Missing pieces of the puzzle, however, still prevent us from clearly understanding the complete picture.
An important area of research for the future might be how to predict -based possibly on novel biomarkers -who will develop cardiac symptoms in response to HER-2-blocking treatment. Improving selectivity of these drugs for breast cancer cells, by identifying further proteins on the cell surface that differentiate between cardiomyocytes and cancer cells, could also be of great importance.
